Glyxambi

Glyxambi

Facts of Glyxambi (empagliflozin)

  • Medicine Name: Glyxambi
  • Generic Name: empagliflozin
  • Approval Date: Jan. 8, 2014
  • Company Name: Boehringer Ingelheim International GmbH
  • Available as (Form & Strength): Tablets: 10 mg empagliflozin/5 mg linagliptin and 25 mg empagliflozin/5 mg linagliptin

What is indication and usage?

  • GLYXAMBI tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate

Limitation of Use

  • GLYXAMBI is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
  • GLYXAMBI has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using GLYXAMBI

What is GLYXAMBI?

GLYXAMBI is a prescription medicine that contains 2 diabetes medicines, empaglifl ozin (JARDIANCE) and linagliptin (TRADJENTA) . GLYXAMBI can be used along with diet and exercise to lower blood sugar in adults with type 2 diabetes when treatment with both empagliflozin (JARDIANCE) and linagliptin (TRADJENTA) is appropriate.

  • GLYXAMBI is not for people with type 1 diabetes.
  • GLYXAMBI is not for people with diabetic ketoacidosis (increased ketones in the blood or urine).
  • If you have had pancreatitis in the past, it is not known if you have a higher chance of getting pancreatitis while you take GLYXAMBI .